CN105859653A - Quetiapine synthesizing method - Google Patents

Quetiapine synthesizing method Download PDF

Info

Publication number
CN105859653A
CN105859653A CN201610282040.9A CN201610282040A CN105859653A CN 105859653 A CN105859653 A CN 105859653A CN 201610282040 A CN201610282040 A CN 201610282040A CN 105859653 A CN105859653 A CN 105859653A
Authority
CN
China
Prior art keywords
quetiapine
acid
formula
synthetic method
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610282040.9A
Other languages
Chinese (zh)
Other versions
CN105859653B (en
Inventor
姚金忠
周宏伟
陈佃鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiaxing University
Original Assignee
Jiaxing University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiaxing University filed Critical Jiaxing University
Priority to CN201610282040.9A priority Critical patent/CN105859653B/en
Publication of CN105859653A publication Critical patent/CN105859653A/en
Application granted granted Critical
Publication of CN105859653B publication Critical patent/CN105859653B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed

Abstract

The invention discloses a quetiapine synthesizing method. O-chlorobenzoic acid with the low price is adopted as a starting material to react with thiophenol, and then ring closure is performed to obtain thioxanthone. Hydroxyl amination and Beckmann rearrangement are performed to obtain a key intermediate dibenzo[b,f][1,4]thiazepines-11-(10H)one, chlorination is performed, then, a reaction is performed on 1-(2-hydroxyethoxy)ethylpiperazine with the existence of acid-binding agent to obtain quetiapine, and the quetiapine and fumaric acid form a salt in an absolute ethyl alcohol system to obtain a product. According to the quetiapine synthesizing method, raw materials are low in price and easy to obtain, the steps are simple, operation is easy, and the cost can be effectively lowered. According to the method, the high-purity quetiapine can be obtained, the liquid phase purity of the obtained semi-fumaric acid quetiapine obtained through salt forming is 99% or above, and the quetiapine synthesizing method can be applied to the field of medicine.

Description

A kind of synthetic method of Quetiapine
Technical field
The invention belongs to pharmaceutical synthesis field, be specifically related to the synthetic method of a kind of Quetiapine.
Background technology
11-{4-[2-(2-(hydroxy ethoxy) ethyl-1-piperazine] } dibenzo [b, f] [Isosorbide-5-Nitrae] sulphur azepine (shown in structure such as formula (I)), is also called Quetiapine, typically sells with the form of hemifumarate. It is the anti-essence of one researched and developed by Britain AstraZeneca UK limited (AstraZeneca drugmaker) God's medicine, in November, 1997, lists in Britain first, is used for treating schizophrenia, has Stronger antipsycholic action and cause less Extra Pyramidal Syndrome.In 2000, domestic quinoline Sulphur puts down the listing that goes through after completing I, II clinical trial phase, and import Quetiapine also completes note the same year Volume also lists at home in calendar year 2001.
About the synthetic method of half quetiapine fumarate, existing more document report, principal synthetic routes There are following several.
Route 1: with 2-diaminodiphenyl sulfide as initiation material, then exists at alkali with phenyl chloroformate Lower generation 2-phenylthiophenyl phenyl carbamate, then carry out molecule inner ring condensation by polyphosphoric acids, Generate dibenzo [b, f] [Isosorbide-5-Nitrae] sulphur azatropylidene-11-(10H) ketone, use POCl3Chlorination obtains 11-chlorodiphenyl And [b, f] [Isosorbide-5-Nitrae] sulphur azatropylidene, then react with Piperazine anhydrous, further with 2-(2 '-chloroethoxy) ethanol Be condensed in the basic conditions and i.e. obtain Quetiapine, Quetiapine in anhydrous ethanol solvent system with half fumaric acid Salt is become i.e. to obtain product.The follow-up improvement to this technique the most first synthesis side chain 1-(2-hydroxy ethoxy) Ethyl piperazidine fragment, then react (WO028458) with 11-chlorodiphenyl also [b, f] [Isosorbide-5-Nitrae] sulphur azatropylidene. There are some defects in this technique: one is that acylation process uses phenyl chloroformate as acylating reagent, atom Utilization rate is relatively low；Two be 2-ADP thiophenol be not the common raw material of industry, need with halo nitre Base benzene and thiophenol are that initiation material is prepared by condensation, reduction two-step reaction, relatively costly.
Route 2: the first step, with the most the same, first synthesizes 2-phenylthiophenyl phenyl carbamate, It not the most directly by cyclizing agent cyclization, but first and side chain N-(2-hydroxyethyl) piperazine condensation, Intermediate sulphur azatropylidene is obtained again, through POCl3 to the hydroxy chloride on its side-chain structure by PPA cyclization Quetiapine is obtained, equally in absolute ethyl alcohol system with ethylene glycol back flow reaction in the basic conditions after change Become salt to obtain product (WO055125) with half fumaric acid.But shortcoming is that the intramolecular ring closure of the 3rd step is anti- Should be more difficult, it may be possible to owing to first connecing the reason that side chain (2-hydroxyethyl) piperazinyl makes steric hindrance increase.
Tan Yun etc. proposed route 3 in 2007: with thiosalicylic acid and o-fluoronitrobenzene as raw material, Prepare 2-nitro-2 '-carboxyl diphenyl sulfide, obtain 2-amino-2 with ferrous sulfate reduction '-carboxyl diphenyl sulfide Ether, is then dehydrated cyclization under effect of sulfuric acid and obtains acid amides, take off one through POCl3 chlorination after-condensation Molecule hydrogen chloride and become with fumaric acid salt obtain half quetiapine fumarate (Chinese Journal of New Drugs 2007,16, 867-868).This route has two obvious shortcomings: one is initiation material thiosalicylic acid and adjacent fluorine nitre Base benzene price is higher, improves production cost；Two is useless with having substantial amounts of iron content after iron reduction nitro Liquid, it is difficult to process.
From process above route it can be seen that mainly heptatomic ring key intermediate dibenzo [b, f] [Isosorbide-5-Nitrae] The synthesis of sulphur azatropylidene-11-(10H) ketone, existing technique is to use polyphosphoric acids cyclization mostly, or uses iron Reduction nitro, does not meets the requirement of Environmental protection.
Summary of the invention
The invention provides the synthetic method of a kind of Quetiapine, the raw material that this synthetic method is used is inexpensive It is easy to get, and the waste liquid produced in course of reaction significantly reduces, to more environment-friendly.
The synthetic method of a kind of Quetiapine, comprises the following steps:
(1) under the effect of copper catalyst, 0-chloro-benzoic acid and benzenethiol generation coupling reaction, To 2-carboxyl diphenyl sulfide；
Shown in the structure such as formula (II) of described 2-carboxyl diphenyl sulfide:
(2) under the effect of acid catalyst, the 2-carboxyl diphenyl sulfide making step (1) obtain occurs Intra-molecular condensation, obtains thioxanthone；
Shown in the structure of described thioxanthone such as formula (III):
(3) thioxanthone step (2) obtained and azanol carry out condensation reaction, obtain thioxanthene Ketoxime；
Shown in the structure such as formula (IV) of described thioxanthene ketoxime:
(4) thioxanthene ketoxime step (3) obtained carries out rearrangement reaction under conditions of acid exists, Obtain 10,11-bis-diphenyl hydrogen [b, f] [1,4] oxygen azatropylidene-11-ketone；
Shown in the structure such as formula (V) of described 10,11-bis-diphenyl hydrogen [b, f] [1,4] oxygen azatropylidene-11-ketone:
(5) under chlorination reagent effect, step (4) obtain 10,11-bis-diphenyl hydrogen [b, f] [Isosorbide-5-Nitrae] Oxygen azatropylidene-11-ketone carries out chlorination, obtains 11-chloro-dibenzo [b, f] [Isosorbide-5-Nitrae] sulphur azatropylidene.
Shown in the structure such as formula (VI) of described 11-chloro-dibenzo [b, f] [1,4] sulphur azatropylidene:
(6) 11-chloro-dibenzo [b, f] [Isosorbide-5-Nitrae] the sulphur azatropylidene in the presence of a base, obtained and 2-(2-hydroxyl Base oxethyl) ethyl piperazidine reacts, and obtains Quetiapine；
Shown in the structure such as formula (VII) of described 2-(2-hydroxyl-oxethyl) ethyl piperazidine:
Shown in the structure of described Quetiapine such as formula (VIII):
(7) salt is become to obtain with fumaric acid in alcoholic solvent the Quetiapine that step (6) obtains described Half quetiapine fumarate；
Shown in the structure such as formula (I) of half described quetiapine fumarate:
The reaction scheme of this synthetic method is as follows:
The synthetic method of the present invention uses cheap and easily-available 0-chloro-benzoic acid as initiation material, is being catalyzed Under the copper effect of dosage, react with benzenethiol, obtain 2-carboxyl diphenyl sulfide, then at acid catalyst Effect under cyclization obtain thioxanthone, then obtain oxime with azanol reaction, then utilize Beckmann Reset and obtain key intermediate dibenzo [b, f] [Isosorbide-5-Nitrae] sulphur azatropylidene-11-(10H) ketone as committed step, Then chloro, reacts obtain Quetiapine with raw material of industry 1-(2-hydroxy ethoxy) ethyl piperazidine, last with Fumaric acid becomes salt to obtain half described quetiapine fumarate.The synthesis step of this synthetic method is less, behaviour Make easily, to be therefore effectively reduced the cost of production.
In step (1), the kind of copper catalyst can produce large effect to reaction yield, described Copper catalyst be copper powder, stannous chloride or copper chloride, now, the yield of reaction is higher.
In step (1), reaction is carried out in a solvent, and described solvent is preferably naphthane.
In step (1), reaction is carried out under the effect of alkali, and described alkali is preferably NaOH.
In step (1), the temperature of reaction is 110～130 DEG C, and reaction temperature is 6～24 hours.
In step (2), described acid catalyst is at least one in the concentrated sulfuric acid and SPA.
In step (2), described Intra-molecular condensation is carried out in a solvent, and described solvent is At least one in benzene, toluene and dimethylbenzene.
In step (2), the temperature of described Intra-molecular condensation is 80～100 DEG C, the reaction time It it is 1～3 hour.
In step (3), described condensation reaction is carried out in a solvent, described solvent be methyl alcohol, At least one in ethanol and isopropanol.
In step (3), the temperature of described condensation reaction is 70～100 DEG C, and the reaction time is 3～10 Hour.
In step (4), described acid is p-methyl benzenesulfonic acid, sulfuric acid or phosphoric acid, the most right Toluenesulfonic acid, when using p-methyl benzenesulfonic acid, reaction yield is the highest.
In step (4), described rearrangement reaction is carried out in a solvent, and described solvent is benzene, first At least one in benzene and dimethylbenzene.
In step (4), the temperature of described rearrangement reaction is 100～130 DEG C, and the reaction time is 12～24 Hour.
In step (5), described chlorination reagent is POCl3 or thionyl chloride, reaction temperature For solvent reflux temperature.
The product that step (5) obtains is adopted after being extracted with ethyl acetate, and organic phase does not concentrate and directly adds Enter alkali to react.
In step (6), described alkali is triethylamine, sodium carbonate or potassium carbonate.
In step (7), described alcoholic solvent is methyl alcohol, ethanol or isopropanol.
The Quetiapine that the present invention obtains obtains half quetiapine fumarate, liquid phase after fumaric acid is acidified into salt Purity, more than 99%, can apply to field of medicaments.
Compared with the existing technology, beneficial effects of the present invention is embodied in:
(1) initiation material used by is cheap and easy to get, is suitable for large-scale production, decreases preparation cost Raw material is cheap and easily-available, and 0-chloro-benzoic acid price is 1.25W/ ton, and other route initiation material neighbour's fluorine nitre Base benzene price is more than 10W/ ton, and cost of material is reduced to only 1/8；
(2) reaction condition is fairly simple, it is easy to operation, does not produce intractable containing in course of reaction Iron waste liquid, environmentally friendly；
(3) the Quetiapine purity obtained is high, can apply to field of medicaments.
Detailed description of the invention
The preparation of embodiment 1 2-carboxyl diphenyl sulfide (compound II)
By 150mL naphthane, 0-chloro-benzoic acid (15.6g, 0.1mol), copper powder (0.32g, 0.005 Mol) join in reaction bulb, when system is down to about 0 DEG C, under stirring, be sequentially added into hydroxide Sodium (6.0g, 0.15mol), benzenethiol (11.1g, 0.1mol), it is warming up to 130 DEG C after finishing Reacting 6 hours (TLC monitoring in course of reaction), react complete cooling, add water 100mL, suction filtration Removing copper powder, filtrate is layered, and aqueous phase to 2-3, separates out a large amount of white solid with salt acid for adjusting pH, Suction filtration obtains crude product 20.5g, yield 89%, purity (HPLC): 97.8%.
Molecular formula: C13H10O2S；Molecular weight: 230.0；MS (m/z): 231.0 (M++H)。
The preparation of embodiment 2 thioxanthone (III)
2-carboxyl diphenyl sulfide (23g, 0.1mol, compound II) is joined in reaction bulb, adds Enter 100mL toluene to dissolve, when ice bath is cooled to about 0 DEG C, drips the 20mL concentrated sulfuric acid, finish After be warming up to 80 DEG C and continue stirring reaction 1h, the TLC monitoring degree that carries out of reaction, after completion of the reaction, Being poured into water by reactant, separatory, organic phase is washed to neutrality, is dried, and removes toluene, uses ethanol It is recrystallized to give faint yellow crude product 16g, yield: 75.5%.Purity (GC): 98.2%.
Molecular formula: C13H8OS；Molecular weight: 212.0；MS (m/z): 213.0 (M+)。
1H NMR(400MHz,CDCl3) δ 8.52 (d, J=8.0Hz, 2H), 7.52-7.43 (m, 4H), 7.37 (t, J=7.6Hz, 2H)；13C NMR(100MHz,CDCl3) δ 179.2,137.1,132.1, 129.6,129.0,126.1,125.7；Fusing point: 207.5 DEG C-209.1 DEG C.
The preparation of embodiment 3 thioxanthene ketoxime (compound VI)
Thioxanthone (21.2g, 0.1mol, compound III) is joined in reaction bulb, adds 100 ML ethanol dissolves, and is subsequently adding hydroxylamine hydrochloride (7.65g, 0.11mol, CAS:5470-11-1), Return stirring reaction 3h, the TLC monitoring degree that carries out of reaction it is warming up to after finishing, after completion of the reaction, Rotation separates out crystal except major part solvent, cooling, and suction filtration obtains white solid 21.1g, yield: 93%. Purity (HPLC): 99.1%.
Molecular formula: C13H9NOS；Molecular weight: 227.0；MS (m/z): 228.0 (M+)。
The preparation of embodiment 4 dibenzo [b, f] [1,4] sulphur azatropylidene-11-(10H) ketone (compound V)
Thioxanthene ketoxime (22.7g, 0.1mol, compound IV) is joined in reaction bulb, adds 100mL dry toluene dissolve, be subsequently adding p-methyl benzenesulfonic acid (0.95g, 0.005mol, CAS: 104-15-4), it is warming up to return stirring after finishing and reacts overnight, the degree that TLC monitoring reaction is carried out, After completion of the reaction, rotation separates out crystal except major part solvent, cooling, and suction filtration obtains white solid 18.5g, Yield: 81.5%.Purity (HPLC): 97.0%.
Molecular formula: C13H9NOS；Molecular weight: 227.0；MS (m/z): 228.0 (M+)。
The preparation of embodiment 5 dibenzo [b, f] [1,4] sulphur azatropylidene-11-(10H) ketone (compound V)
Thioxanthene ketoxime (22.7g, 0.1mol, compound IV) is joined in reaction bulb, adds 100mL xylene soluble, is subsequently adding glacial acetic acid (0.3g, 0.005mol), is warming up to after finishing Return stirring reacts overnight, and the degree that TLC monitoring reaction is carried out, after completion of the reaction, rotation is except major part Solvent, cooling separates out crystal, and suction filtration obtains white solid 17.7g, yield: 78.0%.Purity (HPLC): 95.1%.
Molecular formula: C13H9NOS；Molecular weight: 227.0；MS (m/z): 228.0 (M+)。
The preparation of embodiment 6 dibenzo [b, f] [1,4] sulphur azatropylidene-11-(10H) ketone (compound V)
Thioxanthene ketoxime (22.7g, 0.1mol, compound IV) is joined in reaction bulb, adds 100mL mesitylene dissolve, be subsequently adding p-methyl benzene sulfonic chloride (0.95g, 0.005mol, CAS: 98-59-9), it is warming up to return stirring after finishing and reacts overnight, the degree that TLC monitoring reaction is carried out, After completion of the reaction, rotation separates out crystal except major part solvent, cooling, and suction filtration obtains white solid 15.2g, Yield: 67%.Purity (HPLC): 94%.
Molecular formula: C13H9NOS；Molecular weight: 227.0；MS (m/z): 228.0 (M+)。
Embodiment 7 11-chloro-dibenzo [b, f] [1,4] sulphur azatropylidene (compound VI) and Quetiapine (chemical combination Thing VIII) preparation
By dibenzo [b, f] [Isosorbide-5-Nitrae] sulphur azatropylidene-11-(10H) ketone (11.4g, 50mmol, compound V) Join in reaction bulb, add POCl3 (40g, 260mmol), be warming up to return stirring anti- Answering the degree that 4h, TLC monitoring reaction is carried out, after completion of the reaction, rotation, except solvent, cooling, adds Ethyl acetate and frozen water 150mL, separatory.Organic phase is dried, transfers in reaction bulb, add Potassium carbonate (2.76g, 0.2mol), under ice-water bath drip N-piperazine ethoxy ethanol (9.63g, 55 Mmol, CAS:13349-82-1), room temperature reaction is overnight.Add water 60mL, separatory, organic relevant Dry, it is spin-dried for obtaining grease 14.94g, yield: 78%.Purity (HPLC): 96.8%.
Molecular formula: C21H25N3O2S；Molecular weight: 384.2.0；MS (m/z): 385.2 (M+)。
The preparation of embodiment 8 quetiapine hemifumarate (compound I)
Quetiapine (7.66g, 20mmol) is dissolved in ethanol (40mL), adds fumaric acid (1.16 G, 10mmol, CAS:110-17-8), 8h is stirred at room temperature, filters, it is solid that vacuum drying obtains white Body 8.29g, yield 94%.Purity (HPLC): 99%.
1H NMR(400MHz,DMSO-d6) δ 8.53-8.33 (br, 1H), 7.49-7.27 (m, 5H), 7.16 (m, 2H), 6.98 (dd, J=8.0,1.2Hz, 2H), 6.83 (dd, J=7.6,1.2Hz, 2H), 6.58 (s, 1H), 3.50-3.32 (m, 10H), 2.57-2.44 (m, 6H)；13C NMR(100MHz, DMSO-d6) δ 165.9,159.5,148.0,138.1,133.6,132.9,131.6,131.5,130.7, 128.8,128.5,128.3,126.6,124.6,122.0,71.7,67.2,59.8,56.6,52.2；Fusing point: 173.8℃-175.1℃。

Claims (8)

1. the synthetic method of a Quetiapine, it is characterised in that comprise the following steps:
(1) under the effect of copper catalyst, 0-chloro-benzoic acid and benzenethiol generation coupling reaction, To 2-carboxyl diphenyl sulfide；
Shown in the structure such as formula (II) of described 2-carboxyl diphenyl sulfide:
(2) under the effect of acid catalyst, the 2-carboxyl diphenyl sulfide that step (1) obtains occurs to divide Ring closure reaction in son, obtains thioxanthone；
Shown in the structure of described thioxanthone such as formula (III):
(3) thioxanthone step (2) obtained and azanol carry out condensation reaction, obtain thioxanthene Ketoxime；
Shown in the structure such as formula (IV) of described thioxanthene ketoxime:
(4) thioxanthene ketoxime step (3) obtained carries out rearrangement reaction under conditions of acid exists, Obtain 10,11-bis-diphenyl hydrogen [b, f] [1,4] oxygen azatropylidene-11-ketone；
Shown in the structure such as formula (V) of described 10,11-bis-diphenyl hydrogen [b, f] [1,4] oxygen azatropylidene-11-ketone:
(5) under chlorination reagent effect, step (4) obtain 10,11-bis-diphenyl hydrogen [b, f] [Isosorbide-5-Nitrae] Oxygen azatropylidene-11-ketone carries out chlorination, obtains 11-chloro-dibenzo [b, f] [Isosorbide-5-Nitrae] sulphur azatropylidene；
Shown in the structure such as formula (VI) of described 11-chloro-dibenzo [b, f] [1,4] sulphur azatropylidene:
(6) 11-chloro-dibenzo [b, f] [Isosorbide-5-Nitrae] the sulphur azatropylidene in the presence of a base, obtained and 2-(2-hydroxyl Base oxethyl) ethyl piperazidine reacts, and obtains Quetiapine；
Shown in the structure such as formula (VII) of described 2-(2-hydroxyl-oxethyl) ethyl piperazidine:
Shown in the structure of described Quetiapine such as formula (VIII):
(7) salt is become to obtain with fumaric acid in alcoholic solvent the Quetiapine that step (6) obtains described Half quetiapine fumarate；
Shown in the structure such as formula (I) of half described quetiapine fumarate:
The synthetic method of Quetiapine the most according to claim 1, it is characterised in that step (1) In, described copper catalyst is copper powder, stannous chloride or copper chloride.
The synthetic method of Quetiapine the most according to claim 1, it is characterised in that step (2) In, described acid catalyst is at least one in the concentrated sulfuric acid and SPA.
The synthetic method of Quetiapine the most according to claim 1, it is characterised in that step (3) In, described azanol is hydroxylamine hydrochloride or free azanol.
The synthetic method of Quetiapine the most according to claim 1, it is characterised in that step (4) In, described acid is p-methyl benzenesulfonic acid, sulfuric acid or phosphoric acid.
The synthetic method of Quetiapine the most according to claim 1, it is characterised in that step (5) In, described chlorination reagent is POCl3 or thionyl chloride.
The synthetic method of Quetiapine the most according to claim 1, it is characterised in that step (6) In, described alkali is triethylamine, sodium carbonate or potassium carbonate.
The synthetic method of Quetiapine the most according to claim 1, it is characterised in that step (7) In, described alcoholic solvent is methyl alcohol, ethanol or isopropanol.
CN201610282040.9A 2016-04-29 2016-04-29 A kind of synthetic method of Quetiapine Active CN105859653B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610282040.9A CN105859653B (en) 2016-04-29 2016-04-29 A kind of synthetic method of Quetiapine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610282040.9A CN105859653B (en) 2016-04-29 2016-04-29 A kind of synthetic method of Quetiapine

Publications (2)

Publication Number Publication Date
CN105859653A true CN105859653A (en) 2016-08-17
CN105859653B CN105859653B (en) 2018-12-14

Family

ID=56628980

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610282040.9A Active CN105859653B (en) 2016-04-29 2016-04-29 A kind of synthetic method of Quetiapine

Country Status (1)

Country Link
CN (1) CN105859653B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109705056A (en) * 2019-02-25 2019-05-03 福安药业集团重庆博圣制药有限公司 A kind of preparation method of half quetiapine fumarate of high-purity
CN112939892A (en) * 2021-03-23 2021-06-11 浙江工业大学 Preparation method of quetiapine
CN114149384A (en) * 2021-02-05 2022-03-08 南宁师范大学 Synthetic method of quetiapine
CN114181172A (en) * 2021-12-27 2022-03-15 浙江苏泊尔制药有限公司 Efficient preparation method of quetiapine fumarate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101525333A (en) * 2009-04-07 2009-09-09 华东师范大学 Synthesis method of metixene hydrochloride
CN101830887A (en) * 2010-05-25 2010-09-15 江苏双勤民生冶化设备制造有限公司 Production process of 2-isopropyl thioxanthone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101525333A (en) * 2009-04-07 2009-09-09 华东师范大学 Synthesis method of metixene hydrochloride
CN101830887A (en) * 2010-05-25 2010-09-15 江苏双勤民生冶化设备制造有限公司 Production process of 2-isopropyl thioxanthone

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIH RU HWU ET AL.: "Indian Journal of Chemistry", 《BIOCONJUGATE CHEM》 *
K. NAFARAJAN ET AL.: "Condensed Heterotricycles: Beckmann Rearrangement of Xanthone and Thioxanthone Oximes as a Route to Dibenz[b,f][r,4]-oxazepines and thiazepines", 《INDIAN JOURNAL OF CHEMISTRY》 *
谭云等: "喹硫平的合成改进研究", 《中国新药杂志》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109705056A (en) * 2019-02-25 2019-05-03 福安药业集团重庆博圣制药有限公司 A kind of preparation method of half quetiapine fumarate of high-purity
CN114149384A (en) * 2021-02-05 2022-03-08 南宁师范大学 Synthetic method of quetiapine
CN112939892A (en) * 2021-03-23 2021-06-11 浙江工业大学 Preparation method of quetiapine
CN114181172A (en) * 2021-12-27 2022-03-15 浙江苏泊尔制药有限公司 Efficient preparation method of quetiapine fumarate
CN114181172B (en) * 2021-12-27 2023-12-22 浙江苏泊尔制药有限公司 Efficient preparation method of quetiapine fumarate

Also Published As

Publication number Publication date
CN105859653B (en) 2018-12-14

Similar Documents

Publication Publication Date Title
CN105283442B (en) Method for synthesizing 1 (2 ((2,4 3,5-dimethylphenyl) is thio) phenyl) piperazine
CN105859653A (en) Quetiapine synthesizing method
PT1260512E (en) Novel cyclic amide derivatives
NO340071B1 (en) Propionsyreester derivative
WO2017096996A1 (en) Preparation method for cobimetinib
CN104130212A (en) Synthesis method suitable for industrialized production of vortioxetine hydrobromide
CN107857743A (en) A kind of method for preparing hydrochloric acid roxatidine acetate and intermediate
CN110818661B (en) Preparation method of key intermediate 4-amino-5-halogenobenzofuran-7-carboxylic acid of 5-HT4 receptor agonist
CN108129513A (en) A kind of method for synthesizing Bouguer and replacing Buddhist nun's intermediate
CN103923079A (en) Preparation method of apixaban intermediate
CN101891707B (en) Method for preparing Quetiapine or pharmaceutically acceptable fumarate thereof
CN114292231A (en) 2-methyl-8-substituent-quinoline and preparation method thereof
CN110386918B (en) Preparation method of 5-HT1F agonist compound
JP2004500324A (en) Novel synthesis and crystallization of piperazine ring-containing compounds
CN103864773B (en) Razaxaban and its preparation method of intermediate
CN102234285B (en) Preparation method of olanzapine
US6545149B2 (en) Synthesis and crystallization of piperazine ring-containing compounds
ES2392735T3 (en) Method to produce a nicotinic acid derivative or salt thereof
CN103804221B (en) A kind of Preparation Method And Their Intermediate of 4-(4-aminophenyl)-3-morpholone
CN104045645B (en) The synthetic method of harringtonine C ring intermediates
CN102786463B (en) Method for preparing 5-acetoxyl-3-indole carboxylic acid ethyl ester
CN111039838B (en) Preparation method of 3-acetylmercapto-2-methylpropanoic acid
JPH0272150A (en) Sulfonamide derivative
CN102408374A (en) Synthesis method of 1-(methylsulphonyl)imidazolidin-2-one
CN106748862A (en) A kind of preparation method for promoting gastroenteritic power medicine Itopride Hydrochloride

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant